When we observe an advanced tumor, we are looking at the end product of a complex evolutionary process. The tumor mass is often a chaotic, heterogeneous mixture of cells displaying various states of differentiation and malignancy. For decades, a fundamental question in oncology has remained unresolved: Which specific healthy cell type gave birth to this malignancy?
Pinpointing this "cell of origin" is not merely an academic exercise in lineage tracing. The identity of the initial cell that undergoes transformation dictates the tumor's clinical trajectory, its metastatic potential, and its vulnerability to specific therapies. An oncogenic mutation does not act in a vacuum; its effects are strictly governed by the internal wiring—the epigenetic and transcriptomic landscape—of the cell in which it occurs.
To understand why a tumor behaves the way it does, researchers are shifting from analyzing tumors in isolation to mapping them directly onto the healthy developmental hierarchies from which they arose.
The Context-Dependency of Transformation
Why does the same genetic mutation cause a highly aggressive cancer in one patient but an indolent, benign growth in another? The answer often lies in the target cell's position within its tissue hierarchy.
Consider breast cancer. As Vasudeva Bhat et al. demonstrated in their isolation of a novel basal-like luminal progenitor, mapping these intermediate states is essential for identifying which specific populations serve as the primary targets for oncogenesis. Without this granular map, it is impossible to determine whether aggressive tumor variants stem from a highly specialized progenitor or through stochastic events within a broader population, a dilemma highlighted by Sharon Wang et al. in their work on Pten-deficient basal-like breast cancer.
[Healthy Stem Cell] ──> [Intermediate Progenitor] ──> [Mature Specialized Cell]
│
Oncogenic Hit Here?
▼
[Maturation Arrest]
▼
[Specific Tumor Subtype]
When a mutation strikes a cell, it can hijack the cell's existing self-renewal or migratory programs. If the cell of origin is an early embryonic precursor, the resulting tumor may exhibit profound plasticity and therapeutic resistance. If it strikes a more committed cell, the tumor may remain localized or benign.
Mapping Malignancy to Normal Development
To identify a cell of origin, researchers use a comparative strategy: they build high-resolution reference atlases of healthy tissue development and look for where the tumor's transcriptomic signature "docks."
This approach has been highly successful in pediatric brain tumors, where malignant cells frequently mimic fetal development. For instance, Xiaofei Li et al. constructed a spatiotemporal atlas of the developing human spinal cord to clarify the cellular origins of ependymoma, demonstrating how tumors exploit specific developmental blueprints. Similarly, Oliver L. Eichmüller et al. utilized human cerebral organoids to trace the origins of tumors in Tuberous Sclerosis Complex to a specific, human-amplified progenitor population known as CLIP cells.
By comparing the single-cell RNA sequencing profiles of tumors to these healthy baselines, researchers can identify the exact point of maturation arrest—the developmental stage where a progenitor cell lost the ability to differentiate and began proliferating uncontrollably.
Case Study: Unpacking Medulloblastoma Heterogeneity
Medulloblastoma perfectly illustrates how resolving the cell of origin transforms our understanding of a disease. Once treated as a single monolithic entity, genomic profiling by Giles Robinson et al. proved that medulloblastoma is actually four distinct diseases driven by subgroup-specific mutations.
The structural and behavioral differences between these subgroups are rooted in their distinct cellular lineages:
- Enhancer Hijacking: In the mysterious Groups 3 and 4 medulloblastoma subtypes, Zuguang Gu identified that structural DNA rearrangements reposition powerful super-enhancers to activate oncogenes like PRDM6, a mechanism that relies heavily on the open chromatin landscape of the originating lineage.
- Maturation Arrest: In Sonic Hedgehog (SHH) medulloblastoma, Maxwell P. Gold demonstrated that tumor heterogeneity is fundamentally driven by how far a cell has progressed along its normal developmental trajectory before experiencing maturation arrest.
Resolving Lineage Ambiguity
In many advanced malignancies, the tumor cells are so poorly differentiated (anaplastic) that their origins are obscured. Researchers leverage single-cell transcriptomics and proteomics to peel back these layers of distortion.
For example, in endometrioid endometrial carcinoma, it was long debated whether the cancer originated from epithelial or stromal lineages. Xiaojun Ren et al. resolved this ambiguity by analyzing nearly 100,000 individual cells, proving that the malignancy originates specifically from unciliated glandular epithelial cells.
Similarly, in glioblastoma, the origin of tumor-associated pericytes was highly contested. Cuiying Chu et al. used single-cell analysis to show that these pericytes have a dual origin—some are recruited from normal host tissue, while others are transdifferentiated directly from the tumor cells themselves, actively shaping an immunosuppressive microenvironment.
This problem framing extends across various cancer types where the tissue of origin contains highly diverse cell populations, such as small intestinal neuroendocrine tumors (Felix Bolduan et al., /paper/art_0c0bfc778f7f44e1983a047fac7a7f8a) and epithelial ovarian cancer (Rong Tan et al., /paper/art_ba62a1e5a61c44269197bcfd427721ef).
Lineage Tracing Beyond Oncology
The tools and conceptual frameworks developed for identifying the cell of origin in cancer are deeply intertwined with broader biological questions of cell fate, aging, and tissue regeneration.
Whether tracking how somatic mutations accumulate in healthy mouse tissues to reconstruct anatomical lineage trees (Adam Wasserstrom et al., /paper/art_c20a83361455458296490b38fe9ebf43) or determining whether immunosuppressive cells in aging emerge from immature progenitors or the conversion of mature immune cells (Yaru Su et al., /paper/art_9280f084459f45fdadce8a8a518e5990), the core mechanism remains identical.
By understanding the exact starting state and the precise path a cell takes—whether it leads to a functional organ, an exhausted immune cell, or a malignant tumor—biomedicine can move away from treating symptoms and toward intercepting diseases at their absolute point of origin.
Key Foundational Work
A case of peripheral ameloblastoma (1977) — contributed 1 concept elements to this direction.
Reconstruction of Cell Lineage Trees in Mice (2008) — contributed 1 concept elements to this direction.